Weight Loss as a Therapeutic Goal in PsA PsA is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At #ACR25, 3 compelling studies spanning pharmacologic, lifestyle, and longitudinal https://t.co/Q6IFGn5zCI

IgG4: Rare, but new treatments on the horizon IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis. https://t.co/v07Kp5tQXg https://t.co/rIvOF0mrM1

• https://buff.ly/34QQkA4

Do Patients with Rheumatic Diseases 'Weather' the Storm? Dr. Janet Pope reports on abstract 0164 (Online Patient Survey on the Impact of Extreme Weather Events on Autoimmune and Rheumatic Diseases) presented at #acr25. https://t.co/rY3T6tWsgu https://t.co/vdgT2DB5lH

• Do Patients with Rheumatic Diseases 'Weather' the Storm? | RheumNow

Upadacitinib: revisiting safety data in RA and GCA For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive. Yet in practice, https://t.co/6Wes2npkFd

#ACR25 Best Abstracts - Day 3 Tweeting about an ACR presentation or poster is a skill and sometimes art -- one that is mastered by the RheumNow faculty roving the halls and floors for the best new insights at #ACR25, Here are several of the best abstracts from Day 3, as chosen https://t.co/fOgXSiIWzC

Replay of RheumNow Live 2025 - Rheumatoid Arthritis https://t.co/TMC0A11Eil

• Dr. John Cush

Accelerated Aging in Rheumatic Disease: From Biology to Lifestyle Intervention At #ACR25, the session “27M02: Nutrition for Rheumatic Disease: Where Aging Biology, Sarcopenia, and Diet Intersect” invited the audience to view rheumatic disease through the lens of biological https://t.co/OIgh8JQsFa

A Halloween ACR Guidance (10.31.25) Dr. Jack Cush recaps #ACR25 with suggestions on how to best learn ACR25 content from RheumNow and our Videos and podcasts. https://t.co/ik5n4jA3LK https://t.co/lr65m8kRxx

• https://buff.ly/p2Odily

The Great Debate – Who Really Won? #ACR25 https://t.co/bh0wxXpVXa https://t.co/Wr8eeW1KsQ

• The Great Debate – Who Really Won? | RheumNow

The Decade Ahead: Predicting Long-Term Proteinuria Risk in SLE Lupus nephritis affects almost half of patients with SLE and conveys a mortality rate of up to 30% at 10 years, with at least 10-22% of patients developing end-stage kidney disease. Early detection and diagnosis are https://t.co/ggoA2KsqXg